Nonalcoholic fatty liver disease at the gastroenterology outpatient clinic
Hígado graso no alcohólico en consulta de gastroenterología
Article Sidebar
PDF (Español (España))
FLIP
Main Article Content
Abstract
Introduction: Nonalcoholic fatty liver disease is one of the most common causes of liver disease worldwide. The prevalence in adults is 20 to 30%. It is the leading indication for liver transplantation in Western nations and is linked to metabolic syndrome.
Methodology: A descriptive prospective study was conducted from July 1 2014 to June 30 2016 in 274 patients with fatty liver disease diagnosed by imaging studies at the gastroenterology outpatient clinic of Hospital San José in Popayán, Cauca, Colombia.
Results: Out of 274 participants, 75.5% were women with mean age of 56 years. No antecedents were reported by 37.9% and 19.1% had hypertension, 12.5% dyslipidemia and 8.7% diabetes mellitus; 71.89% lived in urban areas of Popayán. Body mass index was normal in 22.4%, 52.2% had overweight, 17.8% had class i obesity, 5.17% class ii obesity and 2.99% class iii obesity; 59.06% had transaminase levels within the recommendations of the EASL-EASD-EASO.
Conclusions: The study findings are similar to those of previous studies conducted in Colombia: nonalcoholic fatty liver disease affects predominantly women in the sixth decade of life and is linked with components of metabolic syndrome such as hypertension, dyslipidemia and diabetes. The higher number of patients with overweight in our study group compared with other local studies is noteworthy.
Keywords:
Downloads
Article Details
References
2. Lall CG, Aisen AM, Bansal N, Sandrasegaran K. Nonalcoholic fatty liver disease. AJR Am J Roentgenol. 2008;190:993–1002.
3. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73:1961–8.
4. Guía de práctica clínica. Diagnóstico y tratamiento de la enfermedad hepática grasa no alcohólica del adulto. México, D. F.: Secretaría de Salud; 2014. DOI: IMSS-719-14.
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43 2 Suppl 1:S99–112.
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al., American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142:1592–609.
7. Sanyal AJ, American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.
8. Musso G, Gambino R, Cassader M, Pagano G. Metaanalysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–49.
9. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: Noninvasive assessment of non-alcoholic fatty liver disease-The role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–69.
10. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-␣ and -␦, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150, 1147.e5-1159.e5.
11. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al. GOLDEN-505 Investigator Study Group. Phase 3 study to evaluate the efficacy and safety of elafibranor versus placebo in patients with nonalcoholic steatohepatitis (NASH) (RESOLVE-IT). NCT02704403. 2017.
12. Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol. 2012;57:157–66.
13. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. J Hepatol. 2012;56:255–66.
14. Zelber-Sagi S, Salomone F, Webb M, Lotan R, Yeshua H, Halpern Z, et al. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res. 2015;165:428–36.
15. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394–402.
16. Prieto Ortiz J, Sánchez Pardo S, Rojas Díaz L, Huertas Pacheco S. Hígado graso: aspectos clínicos en un centro de tercer nivel en Bogotá - período 2009-2013. Rev Col Gastroenterol. 2014;29:117–24.
17. Vanegas CM, Restrepo C, Vargas N, Marín AE, Martínez LM, Yepes CE, et al. Caracterización de pacientes con enfermedad del hígado graso no alcohólica en un hospital de alta complejidad, Colombia 2013. Rev Col Gastroenterol. 2014;29:342–6.
18. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–31.
19. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434.
20. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol. 1989;20:594.
21. Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274.